{ "meta": { "data_length": 1, "message": "Statement id stmt:hse:00588:h:0 retrieved successfully", "request_url": "https://api.moalmanac.org/statements?statement_id=stmt%3Ahse%3A00588%3Ah%3A0", "status": "success", "status_code": 200, "timestamp_elapsed": 0.00212, "timestamp_received": "2026-10-17T00:00:46.136592+00:00Z", "timestamp_returned": "2026-10-17T00:00:46.138712+00:00Z", "trace_id": "d8b360e3-ce51-4926-8ed2-70853d6915a6" }, "service": { "github": "https://github.com/vanallenlab/moalmanac-db", "name": "Molecular Oncology Almanac", "license": "GPL-2.0", "release": "draft", "url": "https://moalmanac.org", "last_updated": "2026-08-02" }, "data": [ { "id": "stmt:hse:00588:h:0", "type": "Statement", "description": "The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy or in combination with endocrine therapy as a treatment option for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy.", "contributions": [ { "id": "ctrb:hse:2025-05-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2025-05-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00588", "type": "Document", "documentType": "Regulatory approval", "name": "Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf", "urls": [ "https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2020-11-26", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-05-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "direction": "supports", "proposition": { "id": "prop:vtxr:258", "type": "VariantTherapeuticResponseProposition", "predicate": "predictsSensitivityTo", "subjectVariant": { "type": "CategoricalVariant", "description": "Placeholder. Cat-VRS does not yet support sets of categorical variants. See the 'biomarkers' extension for biomarkers associated with this Proposition." }, "conditionQualifier": { "id": "dis:ncit:C9245", "conceptType": "Disease", "name": "Invasive Breast Carcinoma", "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:oncotree:BRCA", "code": "BRCA", "name": "Invasive Breast Carcinoma", "system": "https://oncotree.mskcc.org", "systemVersion": "oncotree_2025_10_03", "iris": [ "https://oncotree.mskcc.org/?version=oncotree_2025_10_03&field=NAME&search=Invasive+Breast+Carcinoma+%28BRCA%29" ] } } ], "extensions": [ { "name": "solid_tumor", "value": true, "description": "Boolean value for if this tumor type is categorized as a solid tumor." } ], "primaryCoding": { "id": "coding:ncit:C9245", "code": "C9245", "name": "Invasive Breast Carcinoma", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C9245" ] } }, "objectTherapeutic": { "id": "tx:ncit:C71721", "conceptType": "Therapy", "name": "Olaparib", "mappings": [ { "relation": "relatedMatch", "coding": { "id": "coding:rxcui:1597582", "code": "1597582", "name": "olaparib", "system": "RxNorm", "systemVersion": "02-Mar-2026", "iris": [ "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=1597582" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:omop:45892579", "code": "45892579", "name": "olaparib", "system": "OMOP", "systemVersion": "v20260227", "iris": [ "https://athena.ohdsi.org/search-terms/terms/45892579" ] } } ], "extensions": [ { "name": "therapy_strategy", "value": [ "PARP inhibition" ], "description": "Associated therapeutic strategy or mechanism of action of the therapy." }, { "name": "therapy_type", "value": "Targeted therapy", "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types" } ], "primaryCoding": { "id": "coding:ncit:C71721", "code": "C71721", "name": "Olaparib", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C71721" ] } }, "extensions": [ { "name": "biomarkers", "value": [ { "id": "bmkr.criterion:48", "present": true, "subject": { "id": "bmkr:48", "type": "CategoricalVariant", "name": "BRCA1 pathogenic variants", "constraints": [ { "type": "DefiningLocationConstraint", "location": { "id": "ga4gh:SL.weCy_6qoSvyzu7QVSpaJMaGWcDUKmqXb", "type": "SequenceLocation", "name": null, "aliases": [], "description": "Sequence spanning the length of refseq:NP_009225.1, the protein product of the MANE Select coding transcript for BRCA1 (refseq:NM_007294.4).", "digest": "weCy_6qoSvyzu7QVSpaJMaGWcDUKmqXb", "sequenceReference": { "id": "ga4gh:SQ.nUzIPnHMyQV52hzgBbKl5vlbSwx8M8_Y", "type": "SequenceReference", "name": "NP_009225.1", "aliases": [ "ensembl:ENSP00000350283.3", "ga4gh:SQ.nUzIPnHMyQV52hzgBbKl5vlbSwx8M8_Y", "refseq:NP_009225.1" ], "description": "The protein product of the MANE Select coding transcript for BRCA1 (refseq:NM_007294.4), corresponding to the Refseq protein accession NP_009225.1.", "moleculeType": "protein", "refgetAccession": "SQ.nUzIPnHMyQV52hzgBbKl5vlbSwx8M8_Y", "residueAlphabet": "aa" }, "start": 0, "end": 1863, "sequence": null }, "relations": [], "matchCharacteristic": { "primaryCoding": { "code": "is_within", "system": "ga4gh-gks-term:location-match" } } }, { "type": "FeatureContextConstraint", "featureContext": { "id": "gene:hgnc:1100", "conceptType": "Gene", "name": "BRCA1", "primaryCoding": { "id": "coding:hgnc:1100", "code": "HGNC:1100", "system": "https://genenames.org", "iris": [ "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1100" ] }, "mappings": [ { "relation": "exactMatch", "coding": { "id": "coding:ensembl:ensg00000012048", "code": "ENSG00000012048", "system": "https://www.ensembl.org", "iris": [ "https://www.ensembl.org/id/ENSG00000012048" ] } }, { "relation": "exactMatch", "coding": { "id": "coding:ncbi:672", "code": "672", "system": "https://www.ncbi.nlm.nih.gov/gene", "iris": [ "https://www.ncbi.nlm.nih.gov/gene/672" ] } }, { "relation": "relatedMatch", "coding": { "id": "coding:refseq:NM_007294.4", "code": "NM_007294.4", "system": "https://www.ncbi.nlm.nih.gov/nuccore", "iris": [ "https://www.ncbi.nlm.nih.gov/nuccore/NM_007294.4" ] } } ] } } ], "extensions": [ { "name": "biomarker_type", "value": "Germline variant" }, { "name": "chromosome", "value": "17" }, { "name": "start_position", "value": null }, { "name": "end_position", "value": null }, { "name": "reference_allele", "value": null }, { "name": "alternate_allele", "value": null }, { "name": "cdna_change", "value": null }, { "name": "protein_change", "value": null }, { "name": "variant_annotation", "value": null }, { "name": "exon", "value": null }, { "name": "rsid", "value": null }, { "name": "hgvsg", "value": null }, { "name": "hgvsc", "value": null }, { "name": "requires_pathogenic", "value": true } ] } }, { "id": "bmkr.criterion:2", "present": true, "subject": { "id": "bmkr:2", "type": "CategoricalVariant", "name": "HER2-negative", "constraints": [], "extensions": [ { "name": "biomarker_type", "value": "Protein expression" }, { "name": "marker", "value": "Human epidermal growth factor receptor 2 (HER2)" }, { "name": "unit", "value": "status" }, { "name": "equality", "value": "=" }, { "name": "value", "value": "Negative" } ] } } ], "description": "The biomarkers associated with this Proposition, each with a `present` flag indicating if the biomarker is present (true) or absent (false). Multiple biomarkers are combined with implied AND logic." } ] }, "strength": { "id": "str:ncit:C25425", "conceptType": "Evidence", "name": "Approval", "mappings": [], "primaryCoding": { "id": "coding:ncit:C25425", "code": "C25425", "name": "Approval", "system": "https://evsexplore.semantics.cancer.gov", "systemVersion": "26.08e", "iris": [ "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C25425" ] } }, "extensions": [ { "name": "status", "value": "Active", "description": "Whether this Statement is Active, Superseded, or Deprecated within moalmanac-db." }, { "name": "indication", "value": { "id": "ind:hse:00588:h", "type": "Indication", "description": "As monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Lynparza's product information fromcites the OlympiA trial, where olaparib was compared against placebo for the treatment of patients with germline BRCA1/2 mutated and HER2-negative high risk early breast cancer.", "contributions": [ { "id": "ctrb:hse:2025-05-01:0", "type": "Contribution", "description": "Indication approved for reimbursement.", "date": "2025-05-01", "contributor": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." } }, { "id": "ctrb:vanallenlab:2024-01-16:0", "type": "Contribution", "description": "Adding HSE approvals for reimbursement to database", "date": "2024-01-16", "contributor": { "id": "agent:user:vanallenlab", "type": "Agent", "agentType": "contributor", "name": "Van Allen lab", "description": "Van Allen lab, Dana-Farber Cancer Institute" } } ], "reportedIn": [ { "id": "doc:hse:00588", "type": "Document", "documentType": "Regulatory approval", "name": "Olaparib (Tablet) Monotherapy. NCCP National SACT Regimen. HSE.", "title": null, "aliases": [], "description": "Olaparib (Tablet) Monotherapy, 2025, version number 5b, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf", "urls": [ "https://healthservice.hse.ie/documents/6397/588_V5b_olaparib_tablet_monotherapy.pdf" ], "doi": null, "pmid": null, "extensions": [ { "name": "agent", "value": { "id": "agent:org:hse", "type": "Agent", "agentType": "organization", "name": "Health Service Executive", "description": "Regulatory agency that approves medicines for reimbursement by the public health system in the Republic of Ireland." }, "description": "The organization that published this document." }, { "name": "company", "value": "", "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents." }, { "name": "drug_name_brand", "value": null, "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "drug_name_generic", "value": null, "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents." }, { "name": "first_publication_date", "value": "2020-11-26", "description": "The publication date for the initial version of this document." }, { "name": "identification_number", "value": null, "description": "Identification number used by the publishing organization." }, { "name": "publication_date", "value": "2025-05-01", "description": "The publication date for the document." }, { "name": "status", "value": "Active", "description": "Whether this document is Active or Deprecated within moalmanac-db." } ] } ], "extensions": [ { "name": "status", "value": "Approved", "description": "Current approval status." }, { "name": "reimbursement_scheme", "value": "CDS", "description": "Current scheme used to reimburse indication." }, { "name": "reimbursement_comment", "value": null, "description": "More details about the current reimbursement scheme(s)." } ] }, "description": "The underlying Indication supporting this Statement." } ] } ] }